Company intelligence / Profile preview

SIAK

Beijing, Beijing, China

Ownership: Private
Development stage: Other

Overview

SIAK-Biotech is a clinical-stage biotechnology company based in Beijing, China, specializing in the development of innovative cell therapies for oncology. The company focuses on Chimeric Antigen Receptor T-cell (CAR-T) technologies, particularly targeting hematological malignancies such as B-cell lymphomas and leukemias. Their lead programs include multi-target CAR-T therapies designed to overcome antigen escape and improve durable response rates in patients with relapsed or refractory cancers. SIAK-Biotech leverages advanced genetic engineering to enhance the precision and efficacy of its cellular immunotherapy pipeline.

Therapeutic areas: Oncology
Modalities: Cell therapyCAR-T cell therapyBiologic
Industry: Biotech

Beyond the preview

Go deeper on SIAK.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SIAK.

Explore the full profile